This clinical-stage biotech develops oral therapeutics for chronic diseases, with a pipeline centered on metabolic and ...
New research presented at the European Congress on Obesity (ECO2026) in Istanbul, Turkey (12–15 May) shows that following ...
Twelve million people lost coverage for Zepbound over the last year. The same number of people lost coverage for Wegovy, according to an analysis by GoodRx, a drug discount website.
Millions of older Americans may have access for the first time to obesity drugs at a low price of $50 a month starting in ...
Peer-reviewed publication highlights preclinical findings demonstrating weight loss, lipid normalization, and reduction ...
Pharma stocks are gaining momentum as obesity drugs, oncology therapies and biotech innovation boost investor optimism.
Scientists developed a five-target obesity drug that outperformed Ozempic in weight loss and blood sugar control in obese ...
Morning Overview on MSN
Scientists create a 'Trojan horse' obesity drug that hijacks GLP-1 receptors to smuggle a second weapon directly into fat cells
A single molecule that tricks its way into fat cells by mimicking a gut hormone, then releases a second drug once inside, has ...
For the time being, tirzepatide remains the superior option for many people thinking about GLP-1 therapy for their obesity or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results